Dendreon Corporation

Dendreon Corporation is a biotechnology company known for developing cancer treatments. Its most notable product is Provenge, a personalized immunotherapy approved for prostate cancer. Provenge works by stimulating the patient's immune system to attack cancer cells. The company has faced financial challenges and underwent bankruptcy in 2014 but has since restructured. Dendreon focuses on advancing cancer therapies and aims to improve outcomes for patients with prostate cancer through innovative approaches. The company's work highlights the ongoing efforts in the medical field to enhance cancer treatment options.